Approval · Notice of Compliance 31938 · 2023
LYNPARZA: Notice of Compliance 31938
Issued October 24, 2023
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 31938
- Date
- October 24, 2023
- Company
- Astrazeneca Canada IncMississauga, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Removal of conditions for platinum-sensitive relapsed (PSR) ovarian cancer as outlined in the Letter of Undertaking.
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| LYNPARZA | Not yet assigned | — |